hepatocellular carcinoma
Conditions
Interventions
As a preoperative chemotherapy, hepatic arterial infusion chemotherapy (HAIC) is performed, regimen of HAIC is New FP therapy. Angiography is performed on Day 1 as induction New FP and bolus injection
Sponsors
Kurume University, Department of Surgery, Division of Hepatobilliary and Pancreatic Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) A case of aged> or =20 years old. 2) Cases of UICC7 StageIIIA, IIIB diagnosed as hepatocellular carcinoma histologically or clinically (imaging diagnosis, tumor marker). 3) Cases of UICC7 StageIIIA, IIIB which can initially perform R0 resection at diagnosis. 4) Cases in which patient consent was obtained in the document after adequate explanation by the attending physician. 5) Patients who can expect survival for more than 3 months. 6) ECOG performance status 0 or 1. 7) Patients who had been preserved adequate major organ functions within 2 weeks before registration (bone marrow, heart, liver, kidney, etc.). Neutrophils> or =1000/mm3 Hb> or =8.5 g/dl Platelet> or =75,000/mm3 AST and ALT< or =200 IU/L Child-Pugh score 7 points or less Total bilirubin 3 mg/dl or less (Excluded after reduction of jaundice cases due to bile duct tumor obstructions) No refractory ascites or hepatic encephalopathy Other major organ functions are well preserved
Exclusion criteria
Exclusion criteria: 1) Patients with history of advanced cancer in other organs within 5 years. 2) A patient who has history of chemotherapy of a regimen including CDDP or 5-FU. 2) Active infectious diseases (except for viral hepatitis) 3) Patients who have a history of allergy to iodine contrast agent, platinum-containing drug, or gelatin-containing drug / food. 4) Pregnant women, breast-feeding women and patients who may be pregnant. Patients who are determined by the attending physician to be inappropriate for this examination for other reasons (in cases where the patient does not obey the instructions or has problems with family cooperation etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The 3 years disease free survival rate after liver surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, disease free survival, response to the preoperative chemotherapy, incidence and degree of side effects of preoperative chemotherapy | — |
Countries
Japan
Contacts
Public ContactYuichi Goto
Kurume University Department of Surgery, Division of Hepatobilliary and Pancreatic Surgery
Outcome results
None listed